Living with COPD: A study on Breztri/Trixeo
Part of Lungs & breathing clinical trials.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with COPD for at least 1 year
- You are between 30 and 80 years old
- You have been prescribed Breztri/Trixeo but have not yet started taking it
- You do not have asthma, active tuberculosis, lung cancer, or other serious lung diseases
- You have not been in the hospital for a heart or lung emergency in the last 3 months
- You have not had a COPD flare-up that required a hospital stay in the last month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination inhaler (fluticasone, formoterol, and glycopyrronium) for people with COPD. It aims to see if this triple therapy can improve breathing and quality of life compared to current treatments.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study looks at how often heart problems or stroke happen in people with COPD after they start a specific “triple therapy” inhaler. It may help doctors understand whether these inhalers change cardiovascular (heart) or cerebrovascular (stroke) risk.
This study tests a medication called Breztri aerosphere (a triple-combination inhaler) to see how safe and well-tolerated it is in Indian patients with COPD who have had recent flare-ups. It may help people who need better control of their breathing symptoms.
This trial tests a once-daily inhaler that combines a long-acting bronchodilator with a corticosteroid to see if it improves breathing, lung function, and quality of life in people with moderate-to-severe COPD who have significant shortness of breath.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.